Cranial Irradiation in EGFR-Mutant NSCLC Brain MetastasesCranial Irradiation in EGFR-Mutant NSCLC Brain Metastases

Is erlotinib plus radiotherapy superior to either therapy alone for brain metastases associated with NSCLC? Translational Lung Cancer Research
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Related Links:

(NRG Oncology) Prophylactic cranial irradiation (PCI), a technique used to prevent the clinical development of brain metastases, is established as a standard approach for many patients with small cell lung cancer (SCLC) after initial therapy. While studies established that PCI decreases the incidence of brain metastases for patients with locally advanced non-small cell lung cancer (LA-NSCLC), there is no established indication for its use for such NSCLC patients.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Authors: Yang H, Wang F, Deng Q, Xiao D, He P, Lin X, He D Abstract Secondary KIT gene amplification leads to tyrosine kinase inhibitor resistance in anaplastic lymphoma kinase (ALK) fusion-positive advanced non-small cell lung cancer (NSCLC). The presence of the 4q12 amplicon causes the activation of downstream mast/stem cell growth factor receptor Kit (c-Kit) or platelet-derived growth factor receptor α (PDGFRA) signaling pathways. Therefore, in the present study, the association between the functional proteins phosphorylated c-Kit (p-c-Kit) and phosphorylated PDGFRA (p-PDGFRA) and the prognosis of ALK fusi...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
ConclusionCombining bone lesion and lung tumor PET/CT features can help stratify risk of bone metastasis in these patients.Key Points•In NSCLC with a single-bone FDG lesion, lesion SUVmaxis useful for differential diagnosis.•CT features of the single-bone FDG lesions provide additional diagnostic value.•High NSCLC SUVmax, greater T stage, and FDG positive nodes also favor metastasis.
Source: European Radiology - Category: Radiology Source Type: research
ber The FLAURA trial established osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), as a viable first-line therapy in non-small cell lung cancer (NSCLC) with sensitizing EGFR mutations, namely exon 19 deletion and L858R. In this phase 3 randomized, controlled, double-blind trial of treatment-naïve patients with EGFR mutant NSCLC, osimertinib was compared to standard-of-care EGFR TKIs (i.e., erlotinib or gefinitib) in the first-line setting. Osimertinib demonstrated improvement in median progression-free survival (18.9 months vs. 10.2 months; hazard ratio 0....
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
AbstractPurposeNon-small cell lung cancer (NSCLC) brain metastases are associated with substantial morbidity and mortality. During recent years, accompanying dramatic improvements in systemic disease control, NSCLC brain metastases have emerged as an increasingly relevant clinical problem. However, optimal surveillance practices remain poorly defined. This purpose of this study was to further characterize the natural history, clinical course and risk factors associated with earlier development of subsequent NSCLC brain metastases to better inform clinical practice and help guide survivorship care.MethodsWe retrospectively ...
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsIn this review, we summarize the recent literature about the use of molecularly targeted agents with concurrent RT in NSCLC patients.
Source: Journal of Radiation Oncology - Category: Cancer & Oncology Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Authors: Protopapa M, Kouloulias V, Nikoloudi S, Papadimitriou C, Gogalis G, Zygogianni A Abstract Non-small cell lung cancer patients with brain metastases have a multitude of treatment options, but there is currently no international and multidisciplinary consensus concerning their optimal treatment. Local therapies have the principal role, especially in symptomatic patients. Advances in surgery and radiation therapy manage considerable local control. Systemic treatments have shown effect in clinical trials and in real life clinical settings; yet, at present, this is restricted to patients with asymptomatic or st...
Source: Journal of Oncology - Category: Cancer & Oncology Tags: J Oncol Source Type: research
We report our results with that approach and the factors influencing outcome. Methods: In the 103 patients who underwent srs for the treatment of 5 or more bmets, primary histology was non-small-cell lung cancer (57% of patients). All patients were grouped by Karnofsky performance status and recursive partitioning analysis (rpa) classification. In our cohort, 72% of patients had uncontrolled extracranial disease, and 28% had stable or responding systemic disease. Previous irradiation for 1-4 bmets had been given to 56 patients (54%). The mean number of treated bmets was 7 (range: 5-19), and the median cumulative bmets ...
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
Despite development of several next-generation tyrosine kinase inhibitors (TKIs), crizotinib remains one of the first-line treatment options for advanced ALK-positive NSCLC and is widely used in situations where ...
Source: Radiation Oncology - Category: Cancer & Oncology Authors: Tags: Research Source Type: research
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Health | Hematology | Lung Cancer | Neurology | Non-Small Cell Lung Cancer | Tarceva